Drugs / Selective Antigen Specific dTβRII-expressing T cells
Selective Antigen Specific dTβRII-expressing T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07172958 | Jan 2026 → Dec 2035 expected | Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma | Children's National Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selective Antigen Specific dTβRII-expressing T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172958 ↗ |
| Modality | Cell therapy | “DNR-TA T cells and B7-H3 CAR T cells will be generated and combined into a final product comprised of the two T cell components combined at a 1:1 ratio.” NCT07172958 ↗ |
| Route | Intravenous | “followed by intravenous infusion of the combined CAR-TA T cell product.” NCT07172958 ↗ |